ClinicalTrials.gg
CompletedNCT01903265BESTFITUpdated Dec 23, 2016Results posted

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

A Phase 2/3 interventional study of TNX-102 SL 2.8mg and Placebo in Primary Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-12-23.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
78th of 320
205 · median 72
Started
2013
with 12 others
Phase 2/3
9 of 369
none open now
Registered
181st of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 78th largest by enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2013, is one of 9 in phase 2/3, and was the 181st registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime have shown promise as a treatment of fibromyalgia, but the drug required new formulation technology for bedtime use. The present trial was designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.

03

Conditions studied

  • Primary Fibromyalgia

Keywords

  • pain
  • sleep
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary Fibromyalgia (ACR criteria)
  • Male or female 18-65 years old
  • For patients with major depressive disorders only: clinically stable, no suicidal risk and stable anti-depressent therapy
  • Willing and able to withdraw specific therapies (ask PI)
  • Medically acceptable form of (female only)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Arthritis, lupus and other systemic auto-immune diseases
  • Regional or persistent pain that could interfere with assessment of fibromyalgia pain
  • Bipolar and psychotic disorders
  • Increased risk of suicide
  • Significant clinical (cardiac, systemic infection, systemic requirement, drug/alcohol abuse) or laboratory abnormalities.
  • Inability to wash-off specific medications (ask PI)
  • Known to cyclobenzaprine
  • Others: seizure disorders, sleep apnea, continuous positive airway pressure (CPAP) use, >40
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    TNX-102 SL 2.8 mg

    Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL 2.8mg

  • Placebo comparator
    Placebo

    Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.

    Drug: Placebo

Interventions

  • Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo

    Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12

    Daily pain scores were assessed using a 24-hour recall response provided by each patient via an interactive voice response system (IVRS) daily telephone diary. Average daily pain was measured using an 11-point (0-10) numerical rating scale (NRS), with higher scores representing worse pain. Jump to control was used to replace missing data in each treatment arm.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. 30% Responder Analysis of IVRS NRS Pain Assessments at Week 12

    The weekly averages of daily pain scores were calculated using the daily, 24-hour-recall, IVRS NRS pain assessments. Patients who had at least a 30% improvement from baseline to week 12 in weekly average of daily pain scores were considered responders.

    Time frame: Baseline, Week 12

  2. Change From Baseline to Week 12 in PROMIS T-score for Sleep Disturbance

    The Patient-Reported Outcome Measurement Information System (PROMIS) sleep disturbance instrument consists of 8 items in which responses are scored 1 to 5 for each item. A higher score on 5 of the 8 items reflects a worse outcome, whereas a higher score on 3 items reflects an improved outcome; therefore, the directionality of the 8 item scores are first synchronized prior to calculation of the total raw score. PROMIS scores are presented as T-scores in which the raw score has been rescaled into a standardized score with a mean of 50 and a standard deviation of 10. Higher T-scores represent more of the concept being measured (in this case, sleep disturbance).

    Time frame: Baseline, Week 12

  3. Patient Global Impression of Change (PGIC) Responder Status ("Very Much Improved" or "Much Improved" vs All Other Categories) at Week 12

    The PGIC is a 7-point scale (1=very much improved; 7=very much worse) that assesses the patient's perception of the overall change in his/her fibromyalgia symptoms since entering the study. Scores of 1 and 2 were considered responders.

    Time frame: Week 12

  4. Change From Baseline to Week 12 in FIQ-R Total Score

    The Fibromyalgia Impact Questionnaire (revised) FIQ-R is made up of 3 domains: functional (9 questions), overall (2 questions) and symptoms (10 questions). All questions are based on an 11-point numerical rating scale (NRS) of 0-10, with 10 being "worst." Total FIQ-R scores can range from 0-100, with higher scores reflecting worsening status. The patient's total score on the FIQ-R was assessed at Visits 2, 3, 4, 5, and 6 (Week 12). Jump to control was used to replace missing data in each treatment arm.

    Time frame: Baseline, Week 12

07

Results

Posted Dec 23, 2016

Participant flow

A total of 205 patients were randomized to either TNX-102 SL or placebo; however, one patient was randomized in error (to the placebo group) and was not dispensed any study drug. Therefore, all disposition and safety tables are based on the safety population of 204 patients. Of these, 174 patients completed the study.

Participant flow — Overall Study
MilestoneTNX-102 SL 2.8 mgPlacebo
Started103102
Completed8985
Not completed1417

Outcome measures

PrimaryMean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12

Daily pain scores were assessed using a 24-hour recall response provided by each patient via an interactive voice response system (IVRS) daily telephone diary. Average daily pain was measured using an 11-point (0-10) numerical rating scale (NRS), with higher scores representing worse pain. Jump to control was used to replace missing data in each treatment arm.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12
units on a scaleTNX-102 SL 2.8 mg TabletsPlacebo
Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12-1.39 ± 0.253-0.95 ± 0.271
Secondary30% Responder Analysis of IVRS NRS Pain Assessments at Week 12

The weekly averages of daily pain scores were calculated using the daily, 24-hour-recall, IVRS NRS pain assessments. Patients who had at least a 30% improvement from baseline to week 12 in weekly average of daily pain scores were considered responders.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
30% Responder Analysis of IVRS NRS Pain Assessments at Week 12
percentage of participantsTNX-102 SL 2.8 mg TabletsPlacebo
30% Responder Analysis of IVRS NRS Pain Assessments at Week 123420.6
SecondaryChange From Baseline to Week 12 in PROMIS T-score for Sleep Disturbance

The Patient-Reported Outcome Measurement Information System (PROMIS) sleep disturbance instrument consists of 8 items in which responses are scored 1 to 5 for each item. A higher score on 5 of the 8 items reflects a worse outcome, whereas a higher score on 3 items reflects an improved outcome; therefore, the directionality of the 8 item scores are first synchronized prior to calculation of the total raw score. PROMIS scores are presented as T-scores in which the raw score has been rescaled into a standardized score with a mean of 50 and a standard deviation of 10. Higher T-scores represent more of the concept being measured (in this case, sleep disturbance).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in PROMIS T-score for Sleep Disturbance
units on a scaleTNX-102 SL 2.8 mg TabletsPlacebo
Change From Baseline to Week 12 in PROMIS T-score for Sleep Disturbance-8.96 ± 0.993-5.13 ± 1.029
SecondaryPatient Global Impression of Change (PGIC) Responder Status ("Very Much Improved" or "Much Improved" vs All Other Categories) at Week 12

The PGIC is a 7-point scale (1=very much improved; 7=very much worse) that assesses the patient's perception of the overall change in his/her fibromyalgia symptoms since entering the study. Scores of 1 and 2 were considered responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Patient Global Impression of Change (PGIC) Responder Status ("Very Much Improved" or "Much Improved" vs All Other Categories) at Week 12
percentage of participantsTNX-102 SL 2.8 mg TabletsPlacebo
Patient Global Impression of Change (PGIC) Responder Status ("Very Much Improved" or "Much Improved" vs All Other Categories) at Week 1230.116.7
SecondaryChange From Baseline to Week 12 in FIQ-R Total Score

The Fibromyalgia Impact Questionnaire (revised) FIQ-R is made up of 3 domains: functional (9 questions), overall (2 questions) and symptoms (10 questions). All questions are based on an 11-point numerical rating scale (NRS) of 0-10, with 10 being "worst." Total FIQ-R scores can range from 0-100, with higher scores reflecting worsening status. The patient's total score on the FIQ-R was assessed at Visits 2, 3, 4, 5, and 6 (Week 12). Jump to control was used to replace missing data in each treatment arm.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in FIQ-R Total Score
units on a scaleTNX-102 SL 2.8 mg TabletsPlacebo
Change From Baseline to Week 12 in FIQ-R Total Score-15.59 ± 2.079-8.54 ± 2.133

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-102 SL 2.8 mg Tablets—0/103 (0%)65/103 (63.1%)
Placebo—1/101 (1%)14/101 (13.9%)
Most frequent serious events
Most frequent serious events
EventTNX-102 SL 2.8 mg TabletsPlacebo
CHOLECYSTITISHepatobiliary disorders0/1031/101
Most frequent other events
Most frequent other events
EventTNX-102 SL 2.8 mg TabletsPlacebo
hypoaesthesia oralGastrointestinal disorders45/1032/101
Product taste abnormalGeneral disorders8/1030/101
SomnolenceNervous system disorders2/1037/101
NauseaGastrointestinal disorders5/1032/101
Back painMusculoskeletal and connective tissue disorders5/1033/101

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TNX-102 SL 2.8 mg TabletsPlaceboTotal
<=18 years000
Between 18 and 65 years10396199
>=65 years055
Age, Continuous
Age, Continuous(years)TNX-102 SL 2.8 mg TabletsPlaceboTotal
Mean50.7 (20 to 64)49.7 (19 to 65)50.2 (19 to 65)
Gender
Gender(Participants)TNX-102 SL 2.8 mg TabletsPlaceboTotal
Female9698194
Male7310
08

Study locations

17 sites
  • 107 Scripps Drive
    Sacramento, California 95825, United States
  • Radiant Research, Inc.
    Denver, Colorado 80239, United States
  • 16176 Cortez Boulevard
    Brooksville, Florida 34601, United States
  • 100 West Gore Street
    Orlando, Florida 32806, United States
  • 3401 North Central Avenue
    Chicago, Illinois 60634, United States
  • 71 Thomas Johnson Drive
    Frederick, Maryland 21702, United States
  • 370 Faunce Corner Road
    North Dartmouth, Massachusetts 02747, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • CRC of Jackson, LLC
    Jackson, Mississippi 39202, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45219, United States
  • 1275 Olentangy River Road
    Columbus, Ohio 43212, United States
  • 18660 Bagley Road
    Middleburg Heights, Ohio 44130, United States
  • 1001 South Market Street
    Mechanicsburg, Pennsylvania 17055, United States
  • 322 Memorial Drive
    Greer, South Carolina 29650, United States
  • 1002 E. South Temple
    Salt Lake City, Utah 84102, United States
  • 1951 152nd Place NE
    Bellevue, Washington 98007, United States
  • 601 Broadway
    Seattle, Washington 98122, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jul 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2013
First posted
Jul 19, 2013
Start
Sep 2013
Primary completionActual
Jul 2014
CompletionActual
Sep 2014
Results first posted
Dec 23, 2016
Last update
Dec 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01903265
Responsible party
Sponsor
First posted
Jul 19, 2013
Start date
Sep 2013
Primary completion
Jul 2014
Completion
Sep 2014
Results posted
Dec 23, 2016
Last update
Dec 23, 2016

Study contacts

Mark R. Schmal
study director · Premier Research Group plc
Daniel J. Clauw, MD
study chair · Ann Arbor, MI

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion